Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth D Cohen

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
World Journal of Oncology|August 14, 2025
Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-AnalysisShreya Shambhavi, Harmanjeet Singh, Ganesh Ramaprasad, et al.
Urology Practice|November 1, 2023
Comparison of ChatGPT and Traditional Patient Education Materials for Men's HealthYash B Shah, Anushka Ghosh, Aaron R Hochberg, et al.
British Journal of Cancer|September 7, 2024
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trialPatrick M Boland, Sarbajit Mukherjee, Iman Imanirad, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
World Journal of Oncology|August 14, 2025
Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-AnalysisShreya Shambhavi, Harmanjeet Singh, Ganesh Ramaprasad, et al.
Urology Practice|November 1, 2023
Comparison of ChatGPT and Traditional Patient Education Materials for Men's HealthYash B Shah, Anushka Ghosh, Aaron R Hochberg, et al.
British Journal of Cancer|September 7, 2024
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trialPatrick M Boland, Sarbajit Mukherjee, Iman Imanirad, et al.
Pageof 3